Literature DB >> 29602817

Somatostatin Receptor Imaging of Neuroendocrine Tumors: From Agonists to Antagonists.

Lisa Bodei1, Wolfgang A Weber2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29602817     DOI: 10.2967/jnumed.117.205161

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


× No keyword cloud information.
  5 in total

Review 1.  Somatostatin receptor PET ligands - the next generation for clinical practice.

Authors:  Elin Pauwels; Frederik Cleeren; Guy Bormans; Christophe M Deroose
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-10-20

Review 2.  Role of PET/CT and Therapy Management of Pancreatic Neuroendocrine Tumors.

Authors:  Diletta Calabrò; Giulia Argalia; Valentina Ambrosini
Journal:  Diagnostics (Basel)       Date:  2020-12-07

3.  First-in-Humans Study of the SSTR Antagonist 177Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy.

Authors:  Richard P Baum; Jingjing Zhang; Christiane Schuchardt; Dirk Müller; Helmut Mäcke
Journal:  J Nucl Med       Date:  2021-03-05       Impact factor: 11.082

Review 4.  Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy.

Authors:  Cristina Barca; Christoph M Griessinger; Andreas Faust; Dominic Depke; Markus Essler; Albert D Windhorst; Nick Devoogdt; Kevin M Brindle; Michael Schäfers; Bastian Zinnhardt; Andreas H Jacobs
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-22

Review 5.  New PET Radiotracers for the Imaging of Neuroendocrine Neoplasms.

Authors:  Emilia Fortunati; Giulia Argalia; Lucia Zanoni; Stefano Fanti; Valentina Ambrosini
Journal:  Curr Treat Options Oncol       Date:  2022-03-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.